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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.08.004There is limited data on the occurrence of coronary artery disease (CAD) in patients with Von Willebrand
disease and the literature is even scarce on their management. We at our institute reviewed the medical
records of 198 patients with Von Willebrand disease over a period of 15 years, of which 6 were found to
have symptomatic CAD. Acute coronary syndrome was noted in 3 patients while the remaining 3 had
stable angina. Cardiac catheterization showed that left main coronary artery was the culprit vessel in
all of these patients. In terms of management, stents were placed in 3 patients, two of them underwent
coronary artery bypass grafting, and the remaining one patient was medically managed. Aspirin, and in
some patients clopidogrel, was well tolerated with minimal side effects.HWith better quality of treatment and treat-ment options, patients with congenitalbleeding disorders now enjoy increased
life expectancy.1,2 A byproduct of this longevity is in-
creased age-related co-morbidities particularly cardio-
vascular and cerebrovascular disease.3–5 Although
clear consensus from the American College of Cardi-
ology and American Heart Association is available for
the management of coronary artery disease (CAD) in
the general population, such evidence-based guidelines
are lacking for the bleeding population.6 All we have
are recommendations based on expert opinion.7 Due
to paucity of data on this subject, physicians are faced
with increased challenges of managing thrombotic
conditions with the use of anti-platelet therapy which
can signiﬁcantly increase the risk of bleeding.
Von Willebrand disease (VWD) is the most com-
mon congenital bleeding disorder in which there is
either a quantitative or qualitative defect in the Von
Willebrand factor.8 Here, in this case series, we report
our center’s experience in the management of CAD in
this speciﬁc patient population.METHODS
This is a single center, retrospective case study con-
ducted at Henry Ford Hospital in Detroit, Michigan.ematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.This study was approved by the institutional review
board of the hospital. Initially, 350 patients with the
diagnosis of presumed VWD were identiﬁed from
the hospital’s administrative database using the
ICD-9 code (286.4), from January 1985 to December
2010. Medical records were reviewed to conﬁrm the
diagnosis. Patients with uncertain diagnosis and/or
incomplete medical records were excluded from the
study. Additionally, patients with acute coronary syn-
drome within 7–10 days of administration of VWF/
FVIII or desmopressin were excluded.
Inclusion criteria
Patients diagnosed with VWD in the setting of a per-
sonal history and or family history of bleeding along
with laboratory criteria of VWF:RCo<50 IU/dL;
VWF:Ag<50 IU/Dl and low to normal levels of
FVIII.9,10
Outcomes
Primary outcome was the incidence of symptomatic
coronary artery disease (CAD) in this patient
population.
Deﬁnitions
Patients were considered to have acute coronary syn-
drome (ACS) if there was documentation of myocar-com 101
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dial infarction, either STEMI (ST segment elevation),
NSTEMI (non-ST segment elevation) or unstable
angina. Characteristics of chest pain along with
changes on the ECG (pathological Q waves, ST-T
segment changes, new onset left bundle branch block)
with or without serial elevation in troponin (cTn)
were used to deﬁne it.11 Patients with features of an-
gina pectoris along with one or more cardiovascular
risk factors were classiﬁed as stable angina.12
Statistical analysis
Categorical variables were expressed as absolute values
and percentages, whereas the continuous variables
were expressed as mean ± standard deviation. Statisti-
cal analysis was carried out using the PASW v18
(Cary, NC, USA).RESULTS
Of the 350 patients identiﬁed over the 15-year period,
198 patients met the inclusion criteria, of which six
(3%) patients had CAD (combination of ACS and
stable angina). The mean age at the time of diagnosis
was 65.5 ± 10.6 years; four out of the six patients
were females. All of them had type-1 VWD. The
mean Framingham score was found to be 17.43 ±
4.32. Among the risk factors, hypertension was seen
in all six patients, followed by hyperlipidemia in three.
Four patients had extensive smoking history, with
three of them being active smokers at the time of diag-
nosis. VWF/FVIII replacement was given both be-
fore and after the procedure. The given dose of
Humate-P was 50U/kg body weight one hour before
the procedure and subsequently the same dose 12 h
after the procedure for the ﬁrst 24–48 h during the
hospital stay.
Below is the detailed description of patient charac-
teristics and management of their CAD.
Patient A
A 75-year-old female with a history of hypertension,
hyperlipidemia and type-1 VWD (VWF:Ag 45%;
VWF:RCo 13%; FVIII:60%). On initial presenta-
tion, she was found to have chest pain and cardiac
troponin elevation. There was no ST segment eleva-
tion on the ECG. Cardiac catheterization showed
80–95% stenosis of proximal and mid left anterior
descending artery (LAD). As this was an acute
presentation requiring immediate intervention, she re-
ceived VWF/FVIII replacement after the procedure.
The decision was made for her to undergo coronary
artery bypass grafting (CABG), following which she
was started on aspirin-81 mg. No bleeding episodesHematowere noted during either procedure. She continued
to be on aspirin and was followed for a period of ﬁve
years, with no recurrence of symptoms.
Patient B
A 58-year-old male with a history of hypertension,
and type-1 VWD (VWF:Ag 14%; VWF:RCo 3%;
FVIII:50%). He was found to have anterior myocar-
dial ischemia on a stress echocardiogram after having
complaints of typical chest pain, though without any
ECG changes and with a normal troponin. Following
this, he underwent cardiac catheterization which
showed 80% occlusion of the LAD, in which a bare
metal stent was placed. He received VWF/FVIII
replacement both before and after the procedure.
There were no bleeding episodes during his hospital
stay. He was started on aspirin-81 mg and clopidogrel
75 mg. Minor bruising was noted within the next
month, at which point clopidogrel was discontinued.
He is close to ten months post operative, with no ma-
jor bleeding episodes.
Patient C
A 74-year-female with a history of hypertension,
hyperlipidemia, insulin dependent diabetes mellitus
and type-1 VWD (VWF:Ag 15%; VWF:RCo 9%;
FVIII:39%) who presented to the emergency depart-
ment (ED) with complaints of chest pain. There were
no ECG changes or troponin elevation. Further work-
up including a cardiac catheterization showed 50%
stenosis of the LAD; no intervention was undertaken
at that time and the decision was made to medically
manage her CAD. She received Humate-P before
and after the procedure, resulting in no bleeding com-
plications. Keeping her bleeding disorder in mind, no
aspirin was given. Five years later, the patient contin-
ues to follow with us, with no recurrence of cardiac
complaints.
Patient D
A 76-year-old female with a history of
hypertension, peripheral vascular disease and type-1
VWD (VWF:Ag 9%; VWF:RCo 13% FVIII:98%).
She suffered a massive ischemic stroke involving the
left middle cerebral artery with residual right sided
hemiparesis. Two years later, nuclear stress test was
done for routine preoperative evaluation for an elec-
tive total knee replacement surgery, which showed
anterior wall ischemia. A decision was made to pro-
ceed with cardiac catheterization, which showed
90% occlusion of the mid LAD, following which a
drug-eluting stent (DES) was placed. She received
factor replacement before and after the procedurel Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
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and was started on aspirin-81 mg and clopidogrel
75 mg. She was followed up for 12 months, during
which she tolerated the dual antiplatelet therapy well.
The only complication noted was self resolving spon-
taneous bruising 6 months into the therapy. However,
she died one year later secondary to failure to thrive.
Patient E
A 52-year-old-female with a history of hypertension,
hyperlipidemia and type-1 VWD (VWF:Ag 15%
VWF:RCo 18%; FVIII:46%) presented to ED with
complaints of shortness of breath and chest pain,
and was found to have ST segment elevation on the
ECG. She was then sent for cardiac catheterization,
was found to have 85% stenosis of the left main artery,
and continued to have chest pains in the lab. An intra-
aortic balloon pump was placed and two days later the
patient underwent CABG. She was given VWF/
FVIII replacement during both the procedures, with-
out signiﬁcant bleeding. She was then started on aspi-
rin 81 mg and continues to be on it, and has been
doing well for the past 10 years. At this time, she
has no history of bleeding or cardiac complaints.
Patient F
A 58-year-old male with a known history of hyperten-
sion and type-1 VWD (VWF:Ag 46%; VWF:RCo
14%; FVIII:70%), presented to ED with complaints
of general tiredness, shortness of breath and fatigue.
He was found to have elevated cardiac troponin with
non ST segment changes on ECG. He underwent
cardiac catheterization which showed 60% occlusion
of the distal LAD; a bare metal stent was placed
and the patient was started on aspirin 81 mg along
with clopidogrel 75 mg. He continued the dual anti-
platelet regimen for a month, during which he noted
spontaneous bruising on his arms. Clopidogrel was
discontinued after one month but aspirin was contin-
ued. He was followed up for a period of six years dur-
ing which no major or minor bleeding episodes were
noted.DISCUSSION
To the best of our knowledge, this is the single largest
case series on the management of CAD in VWD pa-
tients. A Medline search was carried out to identify
similar case reports or case studies, and only eight
independent reports were found in which therapeutic
approaches to ACS in VWD patients were dis-
cussed.13–18 In our population, the incidence of symp-
tomatic CAD was found to be 3%, which is lower
than seen in the general population. Most of the pa-Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.tients were elderly females. Hypertension, hyperlipid-
emia and smoking were the most common risk
factors. The cardiovascular risk factor proﬁle in this
bleeding population is similar to the general popula-
tion.7 Finally, the duration of follow up was
45.6 ± 27.2 months.
In all our patients, the femoral artery was the
choice of access. Factor VWF/FVIII was given in
most cases, both before and after the procedure. Nei-
ther thrombotic nor bleeding complications were ob-
served throughout hospital stay. In some cases
reported in the literature, groin hematoma was noted
after cardiac catheterization. In hemophiliacs, radial
artery access is recommended as there is some data
of lower risk of bleeding, alongside the fact that the
radial artery is easily compressible.19 However, we be-
lieve that if adequate factor replacement is given be-
fore and after the procedure, the risk of bleeding is
minimized even with the femoral approach. In one re-
ported case, a small groin hematoma was noted in
spite of VWF/FVIII replacement.16
Interestingly, occlusion of the left coronary artery
was observed in all six symptomatic patients. This is
the ﬁrst study in which the culprit vessel is reported.
This also suggests that, although ACS rarely occurs in
this population, when it does, it becomes a serious,
life-threatening condition involving the main blood
supply to the heart. We do not have a rationale to ex-
plain this.
Percutaneous coronary artery intervention was car-
ried out in three patients, while CABG was success-
fully performed in two patients. Aspirin was well
tolerated; however, use of dual antiplatelet therapy
lead to spontaneous bruising in two of the three pa-
tients to whom it was administered. This is similar
to other cases reported in the literature where aspirin
is well tolerated but the addition of a second antiplate-
let agent can lead to incidence of spontaneous bleed-
ing.20 Bare metal stent is preferred in cases of
coronary stenting for it precludes the need for longer
duration of antiplatelet therapy.7 One of the patients
in our study received a drug eluting stent (DES), and
was able to tolerate the dual antiplatelet therapy for
12 months. DES could therefore be an option, if
needed.CONCLUSION
CAD is uncommon in patients with VWD. In our
study, we found that patients in ACS emergencies
had safely undergone cardiac catheterization with
minimal complications and tolerated the antiplatelet
therapy well.com 103
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